MECHANISM OF ACTION

The proposed mechanism of action of Defitelio may help restore blood flow through the liver by acting at multiple points along the VOD progressive cascade1,2

See how Defitelio is thought to work within the VOD cascade

pill bottle icon

Learn more about the progressive cascade of VOD from leading experts

Watch videos

Defitelio protects and stabilizes the vasculature of the liver by restoring endothelial cell homeostasis and thrombotic-fibrinolytic balance, ultimately improving hepatic microvascular circulation1-4,a

blood flow reduced unhealthy liver cutout view

aThe mechanism of action of Defitelio has not been fully elucidated.3

Protection and stabilization with Defitelio

aThe mechanism of action of Defitelio has not been fully elucidated.3

restored blood flow
healthy liver

aThe mechanism of action of Defitelio has not been fully elucidated.3

Sinusoidal narrowing and blockage1,2

  • Endothelial cell damage
  • Red blood cells and debris move into the space of Disse
  • Blockage from fibrin deposition, clot formation, and sinusoidal narrowing
  • Reduced blood flow

Protection and stabilization with Defitelio3,5

  • Increased enzymatic activity of plasmin
  • Increased fibrinolysis
  • Endothelial cell proliferation
  • Partial revascularization

Improved hepatic circulation and restored blood flow through the liver2

blood flow reduced unhealthy liver cutout view

Sinusoidal narrowing and blockage1,2

  • Endothelial cell damage
  • Red blood cells and debris move into the space of Disse
  • Blockage from fibrin deposition, clot formation, and sinusoidal narrowing
  • Reduced blood flow
Protection and stabilization with Defitelio

Protection and stabilization with Defitelio3,5

  • Increased enzymatic activity of plasmin
  • Increased fibrinolysis
  • Endothelial cell proliferation
  • Partial revascularization

Improved hepatic circulation and restored blood flow through the liver2

restored blood flow healthy liver

aThe mechanism of action of Defitelio has not been fully elucidated.3

TABLE B: EFFECTS OF DEFITELIO3,6-9

Factor
Function
Defitelio action
Tissue plasminogen activator
catalyzes conversion of plasminogen to plasmin
Thrombomodulin
anticoagulant cofactor
von Willebrand factor
stimulates platelet aggregation
Plasminogen activator inhibitor-1
reduces fibrinolysis

IMPORTANT SAFETY INFORMATION AND INDICATION

Contraindications

Defitelio is contraindicated in the following conditions:

Indication

Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

IMPORTANT SAFETY INFORMATION

Contraindications

Defitelio is contraindicated in the following conditions:

  • Concomitant administration with systemic anticoagulant or fibrinolytic therapy
  • Known hypersensitivity to Defitelio or to any of its excipients

Indication

Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

IMPORTANT SAFETY INFORMATION

Contraindications

Defitelio is contraindicated in the following conditions:

  • Concomitant administration with systemic anticoagulant or fibrinolytic therapy
  • Known hypersensitivity to Defitelio or to any of its excipients

Warnings and Precautions

Hemorrhage

Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.

Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.

Hypersensitivity Reactions

Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.

Most Common Adverse Reactions

The most common adverse reactions (incidence ≥10% and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.

Please see full Prescribing Information.

Indication

Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

IMPORTANT SAFETY INFORMATION

Contraindications

Defitelio is contraindicated in the following conditions:

  • Concomitant administration with systemic anticoagulant or fibrinolytic therapy
  • Known hypersensitivity to Defitelio or to any of its excipients

Warnings and Precautions

Hemorrhage

Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.

Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.

Hypersensitivity Reactions

Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.

Most Common Adverse Reactions

The most common adverse reactions (incidence ≥10% and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.

Please see full Prescribing Information.

CT=computed tomography; CCI=corrected count increment; EBMT=European Society for Blood and Marrow Transplantation; MRI=magnetic resonance imaging; SOS=sinusoidal obstruction syndrome; US=ultrasonography; VOD=veno-occlusive disease.

References: 1. Richardson PG, Palomo M, Kernan NA, et al. The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. Bone Marrow Transplant. 2021;56(12):2889-2896. 2. Richardson PG, Grupp SA, Pagliuca A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. Int J Hematol Oncol. 2017;6(3):75-93. 3. Defitelio [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals. 4. Scalia R, Kochilas L, Campbell B, Lefer AM. Effects of defibrotide on leukocyte-endothelial cell interaction in the rat mesenteric vascular bed: role of P-selectin. Methods Find Exp Clin Pharmacol. 1996;18(10):669-676. 5. Benimetskaya L, Wu S, Voskresenskiy AM, et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood. 2008;112(10):4343-4352. 6. Richardson PG, Corbacioglu S, Ho VT, et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013;12(1):123-136. 7. Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev. 2003;17(2):63-70. 8. Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015;15:130. 9. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85(11):3005-3020.